KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $28.5 million.

  • BeOne Medicines' Change in Account Payables rose 15097.85% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.6 million, marking a year-over-year increase of 265259.99%. This contributed to the annual value of $121.5 million for FY2024, which is 46552.32% up from last year.
  • Per BeOne Medicines' latest filing, its Change in Account Payables stood at $28.5 million for Q3 2025, which was up 15097.85% from -$4.3 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Change in Account Payables peaked at $108.0 million during Q4 2024, and registered a low of -$73.2 million during Q1 2021.
  • Its 5-year average for Change in Account Payables is $8.0 million, with a median of $4.7 million in 2022.
  • Over the last 5 years, BeOne Medicines' Change in Account Payables had its largest YoY gain of 119250.15% in 2024, and its largest YoY loss of 33718.9% in 2024.
  • BeOne Medicines' Change in Account Payables (Quarter) stood at $32.4 million in 2021, then tumbled by 126.42% to -$8.6 million in 2022, then fell by 15.51% to -$9.9 million in 2023, then surged by 1192.5% to $108.0 million in 2024, then tumbled by 73.63% to $28.5 million in 2025.
  • Its last three reported values are $28.5 million in Q3 2025, -$4.3 million for Q2 2025, and -$31.6 million during Q1 2025.